Monday, November 19, 2018 6:40:13 AM
Interesting to see Takeda pressing ahead with the expensive acquisition of Shire
https://www.fiercepharma.com/pharma/former-takeda-chairman-privately-opposes-shire-buyout-ft
but trying to sell off the Shire treatment for inflammatory bowel disease due to its previous acquisition:
https://pharmaphorum.com/news/takeda-proposes-selling-shires-ibd-treatment-after-merger/
The valuation of that sale could be a catalyst with respect to Etrasimod.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM